Home  /  Resource Library  /  Duvelisib, a novel oral dual inhibitor of PI3K-o,y, is clinically active in advanced hematologic malignancies

Duvelisib, a novel oral dual inhibitor of PI3K-o,y, is clinically active in advanced hematologic malignancies

Key point- Duvelisib is clinically and pharmacodynamically active across a range of hematologic malignancies.